Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358399 | 0.80 | LMNA (0.62) | LMNACYP1A2CYP2D6CYP2C19BCHE | |
| Hydrochloric Acid SCHEMBL270476 | 0.78 | LMNA (0.66) | LMNACYP1A2CYP2D6CYP2C19BCHE | |
| Hydrochloric Acid SCHEMBL270477 | 0.78 | LMNA (0.66) | LMNACYP1A2CYP2D6CYP2C19BCHE | |
| Hydrochloric Acid SCHEMBL20291494 | 0.78 | LMNA (0.66) | LMNACYP1A2CYP2D6CYP2C19BCHE | |
| SCHEMBL29025770 | 0.78 | LMNA (0.61) | LMNACYP1A2CYP2D6CYP2C19BCHE | |
| SCHEMBL15883889 | 0.77 | LMNA (0.59) | LMNACYP1A2CYP2D6CYP2C19BCHE | |
| SCHEMBL22227972 | 0.75 | LMNA (0.61) | LMNACYP1A2CYP2D6CYP2C19BCHE | |
| SCHEMBL251109 | 0.75 | LMNA (0.53) | LMNACYP1A2CYP2D6CYP2C19BCHE | |
| SCHEMBL19361299 | 0.74 | LMNA (0.56) | LMNACYP1A2CYP2D6CYP2C19BCHE | |
| SCHEMBL15883906 | 0.74 | BCHE (0.58) | LMNACYP1A2CYP2D6CYP2C19BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275433-B1 | METASTIN DERIVATIVE AND USE THEREOF | UNIV KYOTO (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8765909-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8592379-B2 | Metastin derivative and use thereof | KYOTO UNIVERSITY (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120015868-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2379053-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20110039786-A1 | METASTIN DERIVATIVE AND USE THEREOF | KYOTO UNIVERSITY (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| WO-2008050897-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20060241051-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| EP-1577323-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1063235-B1 | BENZOFURYLPYRONE DERIVATIVES | TEIJIN LTD (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-20030186976-A1 | Benzofurylpyrone derivatives | TEIJIN LIMITED, MICROBIAL CHEMISTRY RESEARCH FOUNDATION | 2003-10-02 | — | — | US | disclosed |
| US-6589984-B1 | Blood cholesterol and triglycerides (TG) themselves are generally insoluble in blood, and they exist as lipoproteins by binding with apolipoproteins. In the body, triglycerides are biosynthesized primarily in the liver from acetyl CoA as | TEIJIN LIMITED (JP) | 2003-07-08 | — | — | US | disclosed |
| EP-1063235-A1 | BENZOFURYLPYRONE DERIVATIVES | TEIJIN LIMITED (JP) | 2000-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015868-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | LMNA 3723/4885CYP1A2 4794/4885CYP2D6 4280/4885 |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | GNRHR, SHBG, MEN1 | LMNA 4034/4885CYP1A2 4601/4885CYP2D6 4367/4885 |
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | KLK3, SHBG, SERPINA3 | LMNA 3348/4885CYP1A2 3450/4885CYP2D6 3818/4885 |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | LMNA 4367/4885CYP1A2 4299/4885CYP2D6 3986/4885 |
| US-20030186976-A1 | Benzofurylpyrone derivatives | PLIN5, ACSL5, PLIN1 | LMNA 2644/4885CYP1A2 542/4885CYP2D6 1756/4885 |
| US-20060241051-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | LMNA 3723/4885CYP1A2 4794/4885CYP2D6 4280/4885 |
| US-20110039786-A1 | METASTIN DERIVATIVE AND USE THEREOF | MEN1, HGF, STMN1 | LMNA 3542/4885CYP1A2 4759/4885CYP2D6 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.